# A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis

> **NCT06660992** · PHASE3 · RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 669 (estimated)

## Conditions studied

- Non-cystic Fibrosis Bronchiectasis

## Interventions

- **DRUG:** HSK31858, tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06660992
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2026-11-28
- **Final completion:** 2027-01-27
- **Target enrollment:** 669 (ESTIMATED)
- **Last updated:** 2024-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06660992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06660992, "A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06660992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*